It's been three months since Lilly launched its obesity pill. Most people are taking Novo's pill instead.WSJ • 07/15/26
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026The Motley Fool • 07/11/26
Novo Nordisk shares dip as latest prescription data points to GLP-1 pill slowdownProactive Investors • 07/08/26
Leading bank backs European pharma as the cleaner alternative to the AI tradeProactive Investors • 07/08/26
Novo Nordisk: The Stock Price Is Only Beginning To Catch Up With Business FundamentalsSeeking Alpha • 07/04/26
Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?Zacks Investment Research • 07/03/26
Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 CoverageZacks Investment Research • 07/01/26
Medicare will start covering obesity drugs for the first time. Here's what patients should knowCNBC • 06/30/26
Novo Nordisk vs. Viking: Which Obesity Drug Stock Is the Better Buy?Zacks Investment Research • 06/29/26